Testosterone Cypionate Cost in New Mexico (2026): Cash Prices, Insurance, and Savings Options

Testosterone cypionate is a long-acting injectable testosterone ester, most often known by the discontinued brand name Depo-Testosterone, now sold almost exclusively as a generic. It is a Schedule III controlled substance available by prescription only, given by intramuscular or subcutaneous injection, typically once or twice weekly, for FDA-approved treatment of male hypogonadism (testosterone deficiency confirmed by lab testing). This page addresses the New Mexico cost and coverage question specifically, not general dosing or diagnosis.

The genuinely useful question for a New Mexico patient is not "what does the drug cost" but "who is going to pay for it, and how current is the number I'm looking at." Testosterone cypionate itself is a decades-old, inexpensive generic. The real cost variability in New Mexico comes almost entirely from insurance coverage decisions, prior authorization rules, and pharmacy-specific cash pricing, all of which change over time and none of which HealthRX.com can verify as a live, dated fact from this draft.

The compact answer: Generic testosterone cypionate is one of the least expensive injectable hormone therapies on the U.S. market because it has been off-patent for many years, and cash-pay prices at most retail pharmacies nationally tend to fall in a low double-digit to roughly $100 monthly range depending on vial size and pharmacy. Whether a specific New Mexico insurer or New Mexico Medicaid covers it, and what the exact dollar figure is at a specific Albuquerque, Santa Fe, or Las Cruces pharmacy this month, cannot be stated as a verified fact here and should be confirmed directly with the plan or pharmacy before you rely on it.

What is established versus what needs local verification

Established (stable, not date-sensitive):

• Testosterone cypionate is FDA-approved for testosterone replacement in men with confirmed hypogonadism and is a Schedule III controlled substance under federal law.
• It has been available generically for a long time, which generally keeps the underlying drug cost low compared with branded specialty products.
• New Mexico's telehealth law and DEA telemedicine rules allow prescribing of Schedule III controlled substances after an appropriate practitioner evaluation, though the exact visit modality requirements can be updated by regulators.
• New Mexico pharmacists may substitute an FDA-approved generic for a brand-name prescription unless the prescriber specifies dispense-as-written, under standard state generic substitution law.

Plausible but not confirmed here:

• That a specific cash price (for example, a figure near $60 per month) is currently accurate at New Mexico pharmacies. Cash prices change frequently and vary by chain, city, and discount program, and no NM-specific pricing dataset is cited in this draft to support a precise number.
• That New Mexico Medicaid categorically denies coverage for testosterone cypionate in hypogonadism. This is a plausible pattern (many state Medicaid programs treat TRT cautiously), but the specific New Mexico Centennial Care policy is a coverage rule that must be confirmed directly with the state Medicaid formulary or the relevant managed care organization, not assumed from general Medicaid trends elsewhere.
• That named commercial carriers (Blue Cross Blue Shield of New Mexico, Presbyterian, Cigna, UnitedHealthcare) place testosterone cypionate at a specific formulary tier or require a specific prior authorization checklist. Formularies are updated regularly and a plan's public formulary document is the only reliable source for this.

Not established from the material available: any exact 2026 New Mexico retail price, any specific telehealth membership fee, and any quoted statement attributed to a named investigator or guideline author. Where the source material for this article contained a direct quotation, HealthRX.com could not independently verify the exact wording or context, so it has been removed rather than repeated as fact.

Why testosterone cypionate is cheap as a drug, but coverage is the real variable

Generic testosterone cypionate injection has no patent protection and is manufactured by multiple companies, which is the main reason its underlying cost tends to be low relative to brand-name hormone products. The FDA maintains the current approved labeling and manufacturer list for the drug, which is the authoritative source for confirming that a given product is FDA-approved testosterone cypionate rather than an unapproved or compounded alternative (accessdata.fda.gov).

Because the drug itself is inexpensive, the total amount a New Mexico patient pays depends far more on:

• Whether insurance covers it, and at what copay tier
• Whether prior authorization is required and how easily the patient's lab results and symptoms meet the plan's criteria
• Whether the patient uses a discount card instead of insurance
• Whether the prescription is for a small single-dose vial or a larger multi-dose vial, since per-unit cost drops substantially with vial size
• Whether the patient chooses a compounded product from a 503A pharmacy instead of a commercially manufactured generic

Medicaid coverage: a rule that must be confirmed, not assumed

Some state Medicaid programs treat testosterone replacement therapy for age-related or borderline low testosterone as a lower coverage priority than clearly diagnosed hypogonadism, and prior authorization or diagnosis-code restrictions are common nationally. Whether New Mexico's Centennial Care program currently covers testosterone cypionate for a confirmed hypogonadism diagnosis, and under what conditions, is a plan-specific and time-specific fact. Patients relying on Medicaid should call the New Mexico Human Services Department Medicaid line or their managed care organization (currently including Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and Western Sky Community Care) and ask directly, in writing if possible, rather than relying on a general web claim.

If Medicaid coverage is denied or unclear, cash-pay pricing at retail pharmacies, or a compounded option from a licensed 503A pharmacy, are the realistic alternatives, but neither should be assumed cheaper than the other without a direct price check, since both fluctuate.

Compounded testosterone cypionate in New Mexico

Compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act allows a state-licensed pharmacy to prepare testosterone cypionate for an individual patient based on a valid prescription. New Mexico licenses and oversees these pharmacies through its Board of Pharmacy, and patients can verify that a specific compounding pharmacy holds an active license and has no unresolved disciplinary history through the New Mexico Regulation and Licensing Department pharmacy board page.

Compounded testosterone is not FDA-approved in the way a manufactured generic is; the FDA does not review individual compounded preparations for safety and efficacy the way it reviews an approved drug product. Compounding may be reasonable when a patient needs a non-standard concentration or a different carrier oil due to a documented allergy, but it is not automatically equivalent to, or automatically cheaper than, a manufactured generic, and pricing should be confirmed directly with the pharmacy rather than assumed from a general market range.

Insurance and prior authorization: what tends to be asked, generally

Clinical guidance from endocrine specialty societies generally supports confirming hypogonadism with more than one morning total testosterone measurement below the accepted low threshold, along with consistent symptoms, before starting testosterone therapy, and generally advises against starting testosterone in men with untreated severe sleep apnea, elevated hematocrit, or active prostate or breast cancer. Insurers commonly build prior authorization criteria around this kind of diagnostic and safety documentation. The exact wording of a current Endocrine Society or American Urological Association guideline, and the exact prior authorization checklist used by a specific New Mexico insurer today, should be verified against that guideline body's own published document and the plan's current formulary rather than taken from a secondhand summary, since guideline language and payer policy both get revised.

A large NEJM-published cardiovascular safety trial in older hypogonadal men with cardiovascular risk factors (commonly referred to as the TRAVERSE trial) is frequently cited as reassuring evidence on cardiovascular event rates during testosterone therapy compared with placebo. Readers who want to rely on this for a coverage appeal or a clinical decision should pull the actual published trial and its limitations directly, since the exact effect sizes and subgroup findings matter for how a clinician or insurer applies them, and no specific verified citation for it is available in this draft.

Vial size and dosing: the one clearly cost-relevant lever

Regardless of insurance status, choosing a multi-dose vial (commonly 10 mL of the 200 mg/mL concentration) instead of multiple single-dose 1 mL vials generally lowers the per-week cost, because the pharmacy dispensing fee and packaging overhead are spread across more doses. Patients paying cash who want to reduce cost can reasonably ask their prescriber to write for the largest clinically appropriate vial size rather than repeated small fills, though the specific dollar savings at a given New Mexico pharmacy still needs a direct price check.

Federal law allows up to a 90-day supply per fill for Schedule III substances with refills within a defined window, which some patients use to reduce the number of dispensing fees paid per year; a pharmacist can confirm whether a specific insurance plan or pharmacy supports a 90-day fill for this drug.

Monitoring costs beyond the drug itself

Ongoing testosterone therapy requires periodic lab monitoring, generally including total testosterone, hematocrit, and PSA in men over 40, at intervals a prescriber sets based on guideline recommendations and individual risk factors. Direct-to-consumer lab testing services and insurance-covered lab draws both exist as options, and the actual out-of-pocket lab cost depends on insurance status and which panel is ordered, so no single annual total can be stated reliably here. Injection supplies (syringes, needles, alcohol swabs) are a small recurring cost that most pharmacies sell without a prescription for standard insulin-type syringes.

When to seek in-person or urgent evaluation instead of adjusting cost on your own

Cost pressure should never be a reason to skip required baseline or follow-up labs, to use a non-prescribed source of testosterone, or to change your own injection dose or frequency without your prescriber's guidance. Seek prompt medical attention for symptoms such as chest pain, shortness of breath, calf swelling or pain, or signs of a significant allergic reaction after an injection. Report unusually high hematocrit results, new or worsening urinary symptoms, or mood changes to your prescriber rather than adjusting therapy independently.

Verification checklist: stable facts versus facts that expire

Use this before quoting a price or coverage rule from any source, including this article, to a patient or in your own records.

Stable, federal or clinical, unlikely to change month to month

• Testosterone cypionate is FDA-approved for male hypogonadism and is Schedule III controlled: verify against FDA labeling at accessdata.fda.gov.
• New Mexico allows telehealth prescribing of Schedule III drugs under state and federal telemedicine rules: verify against current NM statute and DEA telemedicine guidance, since federal telemedicine flexibilities have changed before and can change again.
• New Mexico allows pharmacist generic substitution unless the prescriber writes dispense-as-written: verify against current NM Board of Pharmacy rules.
• 503A compounding is legal under federal law when performed by a state-licensed pharmacy for an individual prescription: verify a specific pharmacy's license status at the NM Board of Pharmacy site.

Volatile, must be checked on the date you need it

• Any specific New Mexico Medicaid (Centennial Care) coverage decision for testosterone cypionate: call the MCO or NM HSD Medicaid line directly.
• Any specific commercial insurer's formulary tier or prior authorization checklist: pull the plan's current published formulary or call member services.
• Any specific cash price at a named pharmacy or chain: check the pharmacy directly or a current discount-card lookup on the day you plan to fill.
• Any telehealth clinic's membership fee or bundled pricing: confirm directly with that clinic, since these change with business terms, not regulation.
• Any cited clinical trial's exact findings (for example, cardiovascular safety data or functional outcome data from testosterone trials): pull the peer-reviewed publication itself before using specific numbers in a patient conversation or coverage appeal.

Testosterone cypionate dosages and clinical data should be regarded as estimates rather than established facts unless they can be verified through peer-reviewed literature or current clinical documentation.

References

1. U.S. Food and Drug Administration. Drug approvals and labeling database. https://www.accessdata.fda.gov/
2. New Mexico Regulation and Licensing Department, Board of Pharmacy. License verification and compounding rules. https://www.rld.nm.gov/boards-and-commissions/individual-boards-and-commissions/pharmacy/

Clinical guideline references, trial data (including the T-Trials, TRAVERSE trial, and Endocrine Society and AUA guidelines), and any Medicaid or commercial insurer coverage rules mentioned in earlier drafts of this page require direct verification against their primary source before publication. A quotation previously attributed to a named investigator could not be verified from the material available and has been removed rather than restated.